The company expects to witness growth in this segment in the to-be-reported quarter, backed by consistent rise in global demand for its peritoneal dialysis (PD) products. Further, the company anticipates experiencing growth for PD patients in the United States on the back of rise in patient volumes.

This apart, the company’s successful rollout of Kaguya in Japan is projected to contribute to the unit’s performance on patient growth.

In January, Baxter announced the Sharesource remote patient management that will be available in 40 countries, which is likely to evolve peritoneal dialysis practice management. Enhancements like this might contribute to the segment’s performance in the soon-to-be-reported quarter.

Global demand for continued renal replacement therapies along with continued momentum in PD is expected to drive growth in this segment in the first quarter. Baxter continues to project growth of around 2% to 3% at constant currency in 2019.

Factors to Influence Q1

The company is likely to deliver better-than-expected results in the to-be-reported quarter driven by anticipated solid show across Renal Care, Advanced Surgery and Acute Therapies businesses. Additionally, increased demand for Baxter’s contract manufacturing services might also contribute to the overall performance in the first quarter.

Baxter expects its business lines to grow in line with their respective market growth rates. The company will also benefit from new product launches.

The company is likely to have exhibited global sales growth in the first quarter driven by performance in Renal Care, Clinical Nutrition and Advanced Surgery businesses.

The company expects to witness a sales decline of around 3% on a reported basis in the first quarter. However, it anticipates growth of about 1% on a constant currency basis and an improvement of 1% to 2% on an operational basis which buoys optimism.

However, the lower cyclophosphamide sales might pose threats to the Integrated Pharmacy Solutions franchise business. This apart, sales at pharmaceuticals business is expected to decline 3% to 4% on a constant currency basis. These can impact the company’s overall performance in the to-be-reported quarter.

What Our Quantitative Model Suggests

Per the proven Zacks model, a company with a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Baxter has a Zacks Rank #3 and an Earnings ESP of 0.00%, a combination that makes surprise prediction difficult.

Please note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revision.

Stocks Worth a Look

Here are some stocks worth considering from the same space as these have the right combination of elements to beat on earnings this time around.

Evolus, Inc. EOLS has an Earnings ESP of +24.39% and a Zacks Rank #3.

NanoString Technologies, Inc. NSTG has an Earnings ESP of +3.08% and a Zacks Rank #3.

Perrigo Company plc PRGO has an Earnings ESP of +3.55% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report